Advertisement

Invited Commentary on Vasudevan, et al: Outcomes of children with well differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731

  • Andrew J. Murphy
    Affiliations
    Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, 38105

    Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, 38105
    Search for articles by this author
      Advances in hepatoblastoma treatment have improved survival but have been accompanied by the chronic toxicities of pediatric cancer therapy. Cisplatin is the cornerstone of chemotherapy treatment for hepatoblastoma. The most frequent long-term complication of hepatoblastoma treatment is cisplatin-related ototoxicity. Among children who receive cisplatin, 25-90% will exhibit measurable hearing loss, impacting language and social development [
      • Sullivan MJ
      Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
      ]. Therefore, efforts to identify children eligible for reduction or elimination of cisplatin-based chemotherapy while maintaining excellent oncologic outcomes are paramount in reducing the long-term toxicities of hepatoblastoma cancer treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sullivan MJ
        Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
        Cancer. 2009; 115: 5623-5626
        • Vasudevan SA
        • Meyers RL
        • Finegold MJ
        • Lopez-Terrada D
        • Ranganathan S
        • Dunn SP
        • et al.
        Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: report from Children's Oncology Group Trial, AHEP0731.
        Journal of Pediatric Surgery. 2022;
        • Yang T
        • Whitlock RS
        • Vasudevan SA.
        Surgical Management of Hepatoblastoma and Recent Advances.
        Cancers (Basel). 2019; 11
        • Malogolowkin MH
        • Katzenstein HM
        • Meyers RL
        • Krailo MD
        • Rowland JM
        • Haas J
        • et al.
        Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.
        J Clin Oncol. 2011; 29: 3301-3306
        • Towbin AJ
        • Meyers RL
        • Woodley H
        • Miyazaki O
        • Weldon CB
        • Morland B
        • et al.
        2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT).
        Pediatr Radiol. 2018; 48: 536-554
        • Katzenstein HM
        • Langham MR
        • Malogolowkin MH
        • Krailo MD
        • Towbin AJ
        • McCarville MB
        • et al.
        Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
        Lancet Oncol. 2019; 20: 719-727